This site is intended for healthcare professionals
  • Home
  • /
  • Guidelines
  • /
  • Cancer; other and unspecified primary
  • /
  • Management of infusion reactions to systemic antic...
Guideline

Management of infusion reactions to systemic anticancer therapy: ESMO Guidelines

Read time: 1 mins
Last updated:30th Jun 2017

Most anticancer treatments carry a risk for infusion reactions which incidence may increase when different agents are administered concomitantly. Although infusion reactions can be allergic or non-immune-mediated, the clinical manifestations are the same and require prompt assessment and appropriate intervention. These new ESMO Clinical Practice Guidelines provide tools to evaluate the risk of infusion reactions, to recognise the early signs and symptoms and include recommendations on how to document and manage them.

 

Read full guideline